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The diagnosis of malignant mesothelioma in serosal effusions
continues to be a major challenge because some of its
cytomorphological features closely resemble adenocarcinomas.
Immunohistochemistry is a valuable tool in the differentiation of
epithelioid mesothelioma from metastatic adenocarcinomas.
However, no single antibody has demonstrated absolute sensitiv-
ity or specificity. In this study, we evaluated the value of immu-
nostaining pattern for podoplanin to differentiate mesothelioma
from adenocarcinomas of various origins.
Cell blocks from previously collected paraffin-embedded cell
blocks of 86 effusions (18 mesothelioma, 35 reactive mesothe-
lium, 9 breast adenocarcinoma, 14 ovarian adenocarcinoma,
and 10 lung adenocarcinoma) were retrieved from the file of the
Department of Pathology at University of Michigan and Lund
University in Sweden and were used for the study. Slides
prepared from the cell blocks were stained for podoplanin.
The percentage of immunostained cells was recorded as follows:
1+ (5–25%), 2+ (26–50%), and 3+ (>50%). A stain result
involving <5% of cells was considered negative. The intensity of
positive results was evaluated as strong, moderate, or weak.
Podoplanin is expressed in 94% of malignant mesothelioma
cases (17/18), 97% (30/31) of cases of reactive mesothelial, 0%
of lung adenocarcinoma cases (0/9), 0% of breast adenocarci-
noma (0/9), and 7% of ovarian adenocarcinoma (1/14). All posi-
tive cases of malignant mesothelioma and reactive mesothelium
showed strong membranous reactivity to podoplanin. The one
positive case of ovarian adenocarcinoma showed a weak mem-
branous podoplanin immunostaining.
On the basis of our results and published data, we believe
that membranous podoplanin immunoreactivity, in conjunction
with calretinin, would be more specific than CK5/6 and WT-1 in
differentiating epithelioid malignant mesothelioma from adeno-
carcinoma of the lung, breast, and ovary. Diagn. Cytopathol.
2010;38:264–269. ' 2010 Wiley-Liss, Inc.
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Malignant pleural mesothelioma arises from the serosal
surfaces of body cavities and is linked to asbestos expo-
sure. It is relatively rare in frequency but with poor clini-
cal outcomes mainly because of lack of effective treat-
ment at present.1,2 Therefore, accurate diagnosis of malig-
nant mesothelioma and correctly differentiating it from
other tumors is imperative for proper patient management.
However, the diagnosis of malignant mesothelioma
continues to be a major challenge because of its ability to
exhibit a broad range of cytomorphological features and
to grow in a wide variety of histologic patterns. The
tumor cells can exhibit epithelial, sarcomatous, and bipha-
sic differentiation.3 Epithelial malignant mesothelioma is
composed of epithelial cells arranged in tubules, papillary
patterns, and many other histologic patterns that closely
resemble adenocarcinomas.4
The diagnosis of epithelioid mesothelioma in the cyto-
logical specimens has been greatly facilitated by the use
of immunohistochemistry in the cell blocks. There are
several lines of evidence indicating that immunohisto-
chemistry is a valuable tool in the differentiation of epi-
thelioid mesothelioma from metastatic adenocarcinomas.5
However, no single antibody has demonstrated absolute
sensitivity or specificity. Therefore, it is a common prac-
tice to use a panel of markers that combine those that are
frequently expressed in mesothelioma with those that are
commonly expressed in carcinomas.
It has been shown that the antibody D2-40, originally
raised against M2A protein expressed in germ cell tumors,
recognizes podoplanin.6 Podoplanin and D2-40 have
recently been recognized to stain mesothelial cells.7–9
Both markers are known to recognize lymphatic endothe-
lium with high sensitivity and specificity.10 Podoplanin is
a sialoglycoprotein that was first recognized as the E11
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antigen, expressed by rat osteoblasts and osteocytes.11
Later, it was named as podoplanin because it was found
on the surface of rat glomerular podocytes and was linked
to the effacement of foot processes in glomerular dis-
ease.12 Currently, it is most widely used as a selective
marker for lymphatic endothelium. It has also been identi-
fied in other normal tissues including mesothelium, myo-
epithelial cells, follicular dendritic cells, and basal kerati-
nocytes, as well as neoplasms including angiosarcomas,
germ cell tumors, and squamous cell carcinomas.13–16
The precise functions of podoplanin are not very clear.
However, podoplanin has been associated with increased tu-
mor cell motility and invasion.17 Podoplanin expression shows
membranous localization in epithelioid mesothelioma and
cytoplasmic localization in sarcomatoid mesothelioma.18
The purpose of this study is to evaluate the prospective
usefulness of podoplanin in the workup of effusions.
Materials and Methods
Cell blocks from previously collected paraffin-embedded
blocks of pleural effusions were retrieved from the file of
the Department of Pathology at University of Michigan,
Ann Arbor, MI and Lund University in Sweden. The
study included a total of 86 cases. These were comprised
of 18 cases of epithelioid mesothelioma, 35 cases of reac-
tive mesothelium, 9 cases of breast ductal adenocarci-
noma, 14 cases of ovarian serous adenocarcinoma, and 10
cases of lung adenocarcinoma. Immunostaining for podo-
planin was performed on paraffin sections as recom-
mended by the manufactures. Mouse monoclonal antibody
against podoplanin was obtained from Vector Laboratory
(Burlingame, CA). Antibody against podoplanin was used
at 1:200 dilution. Briefly, staining procedure was con-
ducted using an automated immunostainer on 5-lm thick
sections of paraffin-embedded tissue. Sections were depar-
affinized in xylene and rehydrated in a descending ethanol
series. The antigens were retrieved using citrate buffer.
Endogenous peroxidase activity was blocked by immer-
sion for 10 minutes in 0.3% hydrogen peroxide in metha-
nol solution, followed by a single wash in phosphate buf-
fered saline (pH 7.4). The immunostaining was developed
using 3,30-diaminobenzidine as chromogen. Appropriate
positive and negative control tissues were added on each
automated immunohistochemistry run to confirm antibody
specificity. Immunoreactivity was scored as negative
(no immunostaining) or positive. Positive results were
evaluated as strong, moderate, or weak. The percentage of
immunostained cells was recorded as follows: 1+ (5–
25%), 2+ (26–50%), and 3+ (>50%). A stain result
involving <5% of cells was considered negative. The in-
tensity of staining was assessed as strong, moderate, or
weak using the podoplanin staining intensity in malignant
mesothelioma cells as a reference for strong intensity.
Results
A total of 86 cases were used in this study. Four cases of
reactive mesothelium and one case of lung adenocarci-
noma were excluded from the study because of very low
cellularity. The immunohistochemical results are summar-
ized in Tables I and II.
Podoplanin was found to be expressed in 17/18 cases
of malignant mesothelioma (94%) with more than 50% of
cells expressing a membranous pattern. The intensity of
membranous staining was strong in eight cases (44%),
moderate in five cases (28%), and weak in four cases
(22%). Another case (6%) showed moderate cytoplasmic
staining in more than 50% of cells (Figs. 1 and 2).
Podoplanin was expressed in all 31 reactive mesothelial
cases (100%), with a membranous pattern in 30/31 of re-
active mesothelial cases (97%) and one (3%) showing
cytoplasmic pattern. One case (3%) showed concomitant
strong membranous and cytoplasmic staining in more
than 50% of cells. More than 50% of reactive mesothelial
cells were positive in 25/31 cases (80%). In 2/31 (7%)
cases, there was membranous staining in 25–50% of reac-









Reactive mesothelia 31 30 97
Mesothelioma 18 17 94
Adenocarcinoma
Lung 9 0 0
Breast 9 0 0
Ovary 14 1 7
Total adenocarcinoma 32 1 3
Table II. Details of Pattern of Podoplanin Immunostaining in Adenocarcinomas and Mesothelioma in Effusions
Malignancy
Pattern of podoplanin immunostaining
Membranous Cytoplasmic
Weak Moderate and strong Weak Moderate and strong
Mesothelioma 4/18 (22%) 13/18 (72%) 0/18 1/18 (6%)
Reactive mesothelium 0/31 30/31 (97%) 0/31 1/31 (3%)
Lung adenocarcinoma 0/9 0/9 1/9 (11%) 0/9
Breast adenocarcinoma 0/9 0/9 2/9 (22%) 0/9
Ovarian adenocarcinoma 1/14 (7%) 0/14 0/14 0/14
PODOPLANIN AND MESOTHELIOMA
Diagnostic Cytopathology, Vol 38, No 4 265
Diagnostic Cytopathology DOI 10.1002/dc
tive mesothelial cells and 3/31cases (13%) had positive
staining in 5–25% of cells. The intensity of membranous
staining was strong in 11 cases (36%), moderate in 10
cases (32%), and weak in 10 cases (32%).
None of the lung adenocarcinoma cases (0/9) had mem-
branous pattern staining (Fig. 3). There was weak cytoplas-
mic staining in 2/9 cases (22%) involving >50% of tumor
cells (Fig. 4). In breast adenocarcinoma cases, none of the
tumor cells showed membranous pattern (Fig. 5). In one
case (11%), the tumor cells did not demonstrate any stain-
ing for podoplanin.
One of 14 cases of ovarian adenocarcinoma (7%) dem-
onstrated weak membranous staining in less than 25% of
cells (Fig. 6).
Discussion
Adenocarcinoma, particularly lung, breast, and ovarian
adenocarcinomas in effusions frequently manifest as
tight cell clusters and present a challenge in separating
them from mesothelial cells on morphologic grounds.
Immunohistochemistry is an invaluable ancillary tech-
nique in differentiating mesothelioma from adenocarci-
noma.
The panel that is used to separate adenocarcinoma from
mesothelioma usually includes one or more of antibodies
that are reactive in mesothelioma but negative in adeno-
carcinoma; in addition, two or more of antibodies that are
reactive in adenocarcinomas and negative or show low
reactivity in mesothelioma. It has been suggested that cal-
Fig. 1. Malignant mesothelioma showing moderately intense membra-
nous staining with podoplanin (3400). [Color figure can be viewed in
the online issue, which is available at www.interscience.wiley.com.]
Fig. 2. Malignant mesothelioma showing strong membranous and focal
moderate nuclear staining with podoplanin (3400). [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
Fig. 3. Lung adenocarcinoma showing no immunoreactivity. Back-
ground mesothelial cells showing membranous podoplanin staining
(3400). [Color figure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
Fig. 4. Lung adenocarcinoma showing focal cytoplasmic podoplanin
immunoreactivity (3400). [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
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retinin,19–22 CK5/CK6,23–25 and WT126–29 are the best
positive predictive markers for epithelioid mesothelioma
and negative mesothelioma markers such as carcinoem-
bryonic antigen, MOC-31,30–33 Ber-EP4,34–36 B72.3,37,38
and CD1539 that are commonly expressed in adenocarci-
nomas. However, although immunohistochemical staining
has proven to be valuable in the differentiation of epithe-
lioid mesothelioma from pulmonary or metastatic adeno-
carcinoma, no single antibody has demonstrated absolute
sensitivity or specificity in making this distinction.5 Con-
sequently, there is a continuous search for a marker with
higher sensitivity and specificity.
D2-40 and podoplanin are two antibodies initially rec-
ognized to stain lymphatic endothelial cells, but expres-
sion of these markers has been more recently described in
mesothelial cells.7–9 Initial reports indicate that this
marker stains virtually 100% of epithelioid mesothelioma
and is a highly useful discriminator between epithelioid
mesothelioma and adenocarcinomas. Recent reports also
indicated that 78% of sarcomatoid mesothelioma do not
exhibit immunoreactivity to D2-40.40,41
It is worth noting that podoplanin expression is not spe-
cific to mesothelioma because it has been reported to be
expressed in various other types of tumors including vascu-
lar tumors, tumors of the central nervous system (CNS),
germ cell tumors, and squamous cell carcinomas.10–13
In this study, podoplanin is expressed in 94% of malig-
nant mesothelioma cases with membranous pattern. The
expression of podoplanin is strong in the majority of
cases. Only one case showed moderate cytoplasmic
expression. This is in accordance with the previous stud-
ies. About 97% (30/31) of cases of reactive mesothelium
express podoplanin with membranous pattern. The inten-
sity of podoplanin staining in reactive mesothelial cases
(36% strong, 36% moderate, and 32% weak) was compa-
rable to that observed in malignant mesothelioma (44%
strong, 28% moderate, and 22% weak). Therefore, on the
basis of these results, podoplanin is not a useful marker
to differentiate between malignant mesothelioma and
reactive mesothelial cells.
Our results demonstrate that none of the cases of lung
and breat adenocarcinomas have expressed membranous
podoplanin immunoreactivity (Figs. 3 and 5). However,
there was cytoplasmic podoplanin immunoreactivity in
1/9 (11%) of lung adenocarcinoma and 2/9 (22%) of
breast carcinoma. In these cases, the cytoplasmic immu-
noreactivity was weak and diffuse. Our findings require
further investigation to determine the significance and
reproducibility of the weak cytoplasmic podoplanin
immunoreactivity in few cases of lung and breast adeno-
carcinomas.
In this study, 1/14 (7%) of cases of ovarian adenocarci-
noma demonstrated a weak membranous immunoreactivity
to podoplanin. Although it is a relatively low percentage,
more cases of ovarian adenocarcinoma should be examined
to determine the accurate percentage of ovarian adenocar-
cinoma that demonstrates membranous immunoreactivity
to podoplanin.
A panel of immunohistochemistry markers is often
used to differentiate mesothelioma from adenocarcinomas.
Most markers are not specific for mesothelioma and cross
react with other malignancies. Calretinin is a calcium-
binding protein expressed in a variety of tissues including
not only mesothelial cells but also adipocytes, neural tis-
sues, and sex cord tumors. The stain is cytoplasmic, but
the combination of both nuclear and cytoplasmic staining
is considered more specific for mesothelial differentia-
tion.19–22 Calretinin stains more than 90% of epithelioid
Fig. 5. Breast adenocarcinoma showing no immunoreactivity. Back-
ground mesothelial cells showing membranous podoplanin staining
(3400). [Color figure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
Fig. 6. Ovarian adenocarcinoma showing no immunoreactivity. Back-
ground mesothelial cells showing membranous podoplanin staining
(3400). [Color figure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
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mesothelioma and the epithelioid component in biphasic
mesotheliomas. Cytokeratin 5/6 stains 65–100% of epithe-
lioid mesothelioma and is highly useful if the differential
diagnosis is essentially restricted to pulmonary adenocar-
cinoma versus epithelioid mesothelioma. However, CK5/6
will also stain a fairly significant percentage of breast and
gynecologic malignancies and is also positive in squa-
mous cell carcinoma.23–25 WT-1 stains mesothelial cells
in a nuclear pattern. It is positive in more than 90% of
epithelioid mesothelioma but it also stains ovarian, perito-
neal serous carcinomas, and small proportion of breast ad-
enocarcinoma.26–29 This diminishes its value when evalu-
ating effusions in women.
In our study, podoplanin membranous immunoreactivity
is highly sensitive and specific for mesothelial cells.
Podoplanin stains 97% of cases of reactive mesothelial,
94% of cases of malignant mesothelioma, and 3% of all
cases of adenocarcinoma (lung, breast, and ovary).
Taken together, we conclude that the membranous
podoplanin immunoreactivity, in conjunction with calreti-
nin, is superior to CK5/6 and WT-1 in differentiating epi-
thelioid malignant mesothelioma from adenocarcinoma of
the lung, breast, and ovary. However, none of them is
useful in differentiating reactive mesothelial cells from
epithelioid malignant mesothelioma.
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